Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
International Journal of Cancer Research
Year: 2007  |  Volume: 3  |  Issue: 3  |  Page No.: 151 - 156

Measurement of Serum Tumor Markers (Alpha-fetoprotein-CA 19.9) and DNA Ploidy in Liver Cirrhosis and Hepatocellular Carcinoma Patients

Ashraf A. Tabll, Mohamed El-Sadany, Tallat Ibrahim, Ibrahim El-Dosoky, Samia Salem and Abdelfattah M. Attallah    

Abstract: The present study aimed to investigate the measurement of serum tumor markers, Alpha-fetoprotein and CA 19.9 and its relation with DNA ploidy of biopsies from liver cirrhosis and hepatocellular carcinoma (HCC). Sera of patients with liver cirrhosis (n = 43) and HCC (n = 73) were tested. Alpha-fetoprotein (AFP) and CA 19.9 were measured according to instruction manual. DNA Flow cytometric analysis was done on liver biopsy from each patient. In liver cirrhosis patients, serum AFP and CA 19.9 were elevated, more than normal values, in 7.1 and 15.8%, respectively. Out of HCC patients, 65.75% showed abnormal elevation of serum AFP while CA 19.9 was found to be elevated abnormally in 48%. The combined measurement of AFP and CA19.9 markers demonstrated that 70% of HCC patients had abnormal elevation of serum concentration of AFP and/or CA 19.9. Aneuploid HCC showed a significant elevation (p<0.001) in tumor markers AFP and CA 19.9 compared with diploid HCC, but this relation was not clear in aneuploid liver cirrhosis. In conclusion, caution is needed in the interpretation of CA 19.9 results in the presence of liver dysfunction. Aneuploid HCC showed a significant elevation in AFP and CA 19.9 tumor markers, but this relation was not clear in aneuploid liver cirrhosis.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
 
 
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility